🔬Deep Research
CAPR — Capricor Therapeutics Inc · catalysts, narrative & risks
Capricor Therapeutics, Inc. (NASDAQ: CAPR) — Point-in-Time Research (as of 2026-11-01)
Recent Catalysts (roughly August–October 2026)
The dominant recent catalysts revolve around the regulatory saga of Deramiocel (CAP-1002) for Duchenne muscular dystrophy (DMD):
AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →